TGFBR1 and endometrial cancer: Herein, we show that the A230V-ALK5 endometrial cancer mutant acts as a partial loss-of-function mutant that has attenuated TGFβ-signaling and exhibits reduced biochemical inhibition by ALK5 inhibitors.